NRSN2 and osteosarcoma: In particular, it has been demonstrated that BMSC-EVs-treated osteosarcoma cells showed increased MALAT1 and NRSN2 expressions, and activated Wnt/β-catenin pathway due to MALAT-1 sponging activity versus miR-143 [131].